[1]
|
Ashworth, T.R. (1869) A Case of Cancer in Which Cells Similar to Those in the Tumours Were Seen in the Blood after Death. The Medical Journal of Australia, 14, 146-147.
|
[2]
|
Mandel, P. and Métais, P. (1948) Les acides nucléiques du plasma sanguin chez l’Homme. Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, 142, 241-243.
|
[3]
|
Engell, H.C. (1955) Cancer Cells in the Circulating Blood: A Clinical Study on the Occurrence of Cancer Cells in the Peripheral Blood an in Venous Blood Draining the Tumor Area at Operation. Acta chirurgica Scandinavica Supplementum, 201, 1-70.
|
[4]
|
Christopherson, W. (1965) Cancer Cells in the Peripheral Blood: A Second Look. Acta Cytologica, 9, 169-174.
|
[5]
|
Goessl, C., Heicappell, R., Münker, R., Anker, P., Stroun, M., Krause, H., Müller, M. and Miller, K. (1998) Microsatellite Analysis of Plasma DNA from Patients with Clear Cell Renal Carcinoma. Cancer Research, 58, 4728-4732.
|
[6]
|
Nawroz, H., Koch, W., Anker, P., Stroun, M. and Sidransky, D. (1996) Microsatellite Alterations in Serum DNA of Head and Neck Cancer Patients. Nature Medicine, 2, 1035-1037. https://doi.org/10.1038/nm0996-1035
|
[7]
|
Chen, X.Q., Stroun, M., Magnenat, J.L., Nicod, L.P., Kurt, A.M., Lyautey, J., Lederrey, C. and Anker, P. (1996) Microsatellite Alterations in Plasma DNA of Small Cell Lung Cancer Patients. Nature Medicine, 2, 1033-1035.
https://doi.org/10.1038/nm0996-1033
|
[8]
|
Ranuncolo, S.M. (2016) Towards the Dreamed Biomarkers? Journal of Molecular Biomarkers & Diagnosis, S2, e002.
|
[9]
|
Alix-Panabières, C. and Pantel, K. (2013) Circulating Tumor Cells: Liquid Biopsy of Cancer. Clinical Chemistry, 59, 110-118.
|
[10]
|
De Mattos-Arruda, L., Cortes, J., Santarpia, I., Vivancos, A., Tabernero, J., Reis, J.S., et al. (2013) Circulating Tumour Cells and Cell-Free DNA as Tools for Managing Breast Cancer. Nature Reviews Clinical Oncology, 10, 377-389.
https://doi.org/10.1038/nrclinonc.2013.80
|
[11]
|
Crowley, E., Di Nicolantonio, F., Loupakis, F. and Bardelli, A. (2013) Liquid Biopsy: Monitoring Cancer Genetics in the Blood. Nature Reviews Clinical Oncology, 10, 472-484. https://doi.org/10.1038/nrclinonc.2013.110
|
[12]
|
Scher, H.L., Moris, M.J., Larson, S. and Heller, G. (2013) Validation and Clinical Utility of Prostate Cancer Biomarkers. Nature Reviews Clinical Oncology, 10, 225-234. https://doi.org/10.1038/nrclinonc.2013.30
|
[13]
|
Woodcock, J. and Woosley, R. (2008) The FDA Critical Pathway Initiative and Its Influence on New Drug Development. Annu. Rev. Med., 59, 1-12.
https://www.c-path.org/pdf/FDAcriticalpathinitiativeinfluenceonnewdrugdevelopmentWoodcockWoosley.pdf
|
[14]
|
Hayes, D.F., Allen, J., Compton, C., Gustavsen, G., Leonard, D.G., McCormack, R., et al. (2013) Breaking a Vicious Cycle. Science Translational Medicine, 5, 196cm6.
https://doi.org/10.1126/scitranslmed.3005950
|
[15]
|
Center for Drug Evaluation and Research (CDER), Food & Drug Administration, United States Department of Health and Human Services (2011) Guidance for Industry: E16 Biomarkers Related to Drugs or Biotechnology Product Development: Context, Structure and Format of Quantification Submissions.
|
[16]
|
Michael, C. and Ball, J. (2010) Institute of Medicine (U.S.) Committee on Qualifications of Biomarkers and Surrogate Endpoints in Chronic Disease. Evaluation of Biomarkers and Surrogate Endpointsin Chronic Disease. National Academic Press, Washington DC, 314.
|
[17]
|
Parkinson, D.R., Dracopoli, N., Petty, B.G., Compton, C., Cristofanilli, M., Deisseroth, A., et al. (2012) Considerations in the Development of Cirsulting Tumor Cell Technology for Clinical Use. Journal of Translational Medicine, 10, 138.
https://doi.org/10.1186/1479-5876-10-138
|
[18]
|
Karabacak, N.M., Spuhler, P.S., Fachin, F., Lim, E.J., Pai, V., Ozkumur, E., Martel, J.M., Kojic, N., Smith, K., Chen, P., Yang, J., Hwang, H., Morgan, B., Trautwein, J., Barber, T.A., Stott, S.L., Maheswaran, S., Kapur, R., Haber, D.A. and Toner, M. (2014) Microfluidic, Marker-Free Isolation of Circulating Tumor Cells from Blood Samples. Nature Protocols, 9, 694-710. https://doi.org/10.1038/nprot.2014.044
|
[19]
|
Yap, T.A., Lorente, D., Omlin, A., Olmos, D. and de Bono, J.S. (2007) Circulating Tumor Cells: A Multifunctional Biomarker. Clinical Cancer Research, 20, 2553-2568. https://doi.org/10.1158/1078-0432.CCR-13-2664
|
[20]
|
Nagrath, S., Sequist, L.V., Maheswaran, S., Bell, D.W., Irimia, D., Ulkus, L., Smith, M.R., Kwak, E.L., Digumarthy, S., Muzikansky, A., Ryan, P., Bails, U.J., Tompkins, R.G., Haber, D.A. and Toner, M. (2007) Isolation of Rare Circulating Tumour Cells in Cancer Patients by Microchip Technology. Nature, 450, 1235-1239.
https://doi.org/10.1038/nature06385
|
[21]
|
Satelli, A., Mitra, A., Cultrera, J.J., Davarie, M., et al. (2014) Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells. Cancer Research, 74, 1645-1650. https://doi.org/10.1158/0008-5472.CAN-13-1739
|
[22]
|
Fleischhacker, M. and Schmidt, B. (2007) Circulating Nucleic Acids (CNAs) and Cancer—A Survey. Biochimica et Biophysica Acta, 1775, 181-232.
|
[23]
|
Stroun, M., Anker, P., Maurice, P., Lyautey, J., Lederrey, C. and Beljansky, M. (1989) Neoplastic Characteristics of the DNA Found in the Plasma of Cancer Patients. Oncology, 46, 318-322. https://doi.org/10.1159/000226740
|
[24]
|
Thierry, A.R., Messaoudi, E.I., Gahan, P.B., Anker, P. and Stroun, M. (2016) Origins, Structures and Functions of Circulating DNA in Oncology. Cancer and Metastasis Reviews, 35, 347-376. https://doi.org/10.1007/s10555-016-9629-x
|
[25]
|
Gahan, P.B. and Stroun, M. (2010) The Virtosome—A Novel Cytosolic Informative Entity and Intercellular Messenger. Cell Biochemistry and Function, 28, 529-538.
https://doi.org/10.1002/cbf.1690
|
[26]
|
Mouliere, F. and Thierry, A.R. (2012) The Importance of Examining the Proportion of Circulating DNA Originating from Tumor, Microenvironment and Normal Cells in Colorectal Cancer Patients. Expert Opinion on Biological Therapy, 12, S209-S215. https://doi.org/10.1517/14712598.2012.688023
|
[27]
|
Rykova, E.Y., Morozkin, E.S., Ponomaryova, A.A., Loseva, E.M., Zaporozhchenko, I.A., Cherdyntseva, N.V. and Laktionov, P.P. (2012) Cell-Free and Cell-Bound Circulating Nucleic Acid Complexes: Mechanisms of Generation, Concentration and Content. Expert Opinion on Biological Therapy, 12, S141-S153.
https://doi.org/10.1517/14712598.2012.673577
|
[28]
|
Laktionov, P.P., Tamkovich, S.N., Rykova, E.Y., Bryzgunova, O.E., Starikov, A.V., Kuznetsova, N.P. and Vlassov, V.V. (2004) Cell-Surface-Bound Nucleic Acids: Free and Cell-Surface-Bound Nucleic Acids in Blood of Healthy Donors and Breast Cancer Patients. Annals of the New York Academy of Sciences, 1022, 221-227.
https://doi.org/10.1196/annals.1318.034
|
[29]
|
Fan, H.C., Blumenfeld, Y.J., Chitkara, U., Hudgins, L. and Quake, S.R. (2008) Noninvasive Diagnosis of Fetal Aneuploidy by Shotgun Sequencing DNA from Maternal Blood. Proceedings of the National Academy of Sciences of the United States of America, 105, 16266-16271. https://doi.org/10.1073/pnas.0808319105
|
[30]
|
Lo, Y.M.D., Chan, K.C.A., Sun, H., Chen, E.Z., Jiang, P., Lun, F.M.F., Zheng, Y.W., Leung, T.Y., Lau, T.K., Cantor, C.R., et al. (2010) Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus. Science Translational Medicine, 2, 61ra91. https://doi.org/10.1126/scitranslmed.3001720
|
[31]
|
Holdenrieder, S., Stieber, P., Chan, L.Y.S., Geiger, S., Kremer, A., Nagel, D. and Lo, Y.M.D. (2005) Cell-Free DNA in Serum and Plasma: Comparison of ELISA and Quantitative PCR. Clinical Chemistry, 51, 1544-1546.
https://doi.org/10.1373/clinchem.2005.049320
|
[32]
|
Wimberger, P., Roth, C., Pantel, K., Kasimir-Bauer, S., Kimmig, R. and Schwarzenbach, H. (2010) Impact of Platinum-Based Chemotherapy on Circulating Nucleic Acid Levels, Protease Activities in Blood and Disseminated Tumor Cells in Bone Marrow of Ovarian Cancer Patients. International Journal of Cancer, 128, 2572-2580. https://doi.org/10.1002/ijc.25602
|
[33]
|
Snyder, M.W., Kircher, M., Hill, A.J., Daza, R.M. and Schendure, J. (2016) Cell-Free DNA Comprises an in Vivo Nucleosome Footprint That Informs Its Tissues-ofOrigin. Cell, 164, 57-68. https://doi.org/10.1016/j.cell.2015.11.050
|
[34]
|
Bidard, F.C., Weigelr, B. and Reis-Filho, J.S. (2013) Going with the Flow: From Circulating Tumor Cells to DNA. Science Translational Medicine, 5, 207ps14.
https://doi.org/10.1126/scitranslmed.3006305
|
[35]
|
Chevillet, J.R., Kang, Q., Ruf, I.K., Briggs, H.A., Vojtech, L.N., Hughes, S.M. and Tewari, M. (2014) Quantitative and Stoichiometric Analysis of the microRNA Content of Exosomes. Proceedings of the National Academy of Sciences of the United States of America, 111, 14888-14893. https://doi.org/10.1073/pnas.1408301111
|
[36]
|
De Jong, O.G., Van Balkom, B.W.M., Schiffelers, R.M., Bouten, C.V.C. and Verhaar, M.C. (2014) Extracellular Vesicles: Potential Roles in Regenerative Medicine. Frontiers in Immunology, 5, 608. https://doi.org/10.3389/fimmu.2014.00608
|
[37]
|
Tetta, C., Ghigo, E., Silengo, L., Deregibus, M.C. and Camussi, G. (2013) Extracellular Vesicles as an Emerging Mechanism of Cell-to-Cell Communication. Endocrine, 44, 11-19. https://doi.org/10.1007/s12020-012-9839-0
|
[38]
|
Thakur, B.K., Zhang, H., Becker, A., Matei, I., Huang, Y., Costa-Silva, B.K. and Lyden, D. (2014) Double-Stranded DNA in Exosomes: A Novel Biomarker in Cancer Detection. Cell Research, 24, 766-769. https://doi.org/10.1038/cr.2014.44
|
[39]
|
Hohaus, S., Giachelia, M., Massini, G., Mansueto, G., Vannata, B., Bozzoli, V., Criscuolo, M., D’Alò, F., Martini, M., Larocca, L.M., Voso, M.T. and Leone, G. (2009) Cell-Free Circulating DNA in Hodgkin’s and Non-Hodgkin’s Lymphomas. Annals of Oncology, 20, 1408-1413. https://doi.org/10.1093/annonc/mdp006
|
[40]
|
The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A Predictive Model for Aggressive Non-Hodgkin’s Lymphoma. The New England Journal of Medicine, 329, 987-994. https://doi.org/10.1056/NEJM199309303291402
|
[41]
|
Basso, K. and Dalla-Favera, R. (2011) Germinal Centres and B Cell Lymphomagenesis. Nature Reviews Inmunology, 15, 172-184.
https://doi.org/10.1038/nri3814
|
[42]
|
Camus, V., Sarafan-Vasseur, N., Bohers, E., Dubois, S., Mareschal, S., Bertrand, P., Viailly, P.J., Ruminy, P., Maingonnat, C., Lemasie, E., Stamatoullas, A., Picquenot, J.M., Cornic, M., Beaussire, L., Bastard, Ch., Frebourg, T., Tilly, H. and Jardin, F. (2016) Digital PCR for Quantification of Recurrent and Potentially Actionable Somatic Mutations in Cirsulating Free DNA from Patients with Diffuse Large B-Cell Lymphoma. Leukemia & Lymphoma, 57, 2171-2179.
https://doi.org/10.3109/10428194.2016.1139703
|
[43]
|
Garcia, V., Garcia, J.M., Silva, J., Martin, P., Pena, C., Dominguez, G., Diaz, R., Herrera, M., Maximiano, C., Sabin, P., Rueda, A., Cruz, M.A., Rodriguez, J., Canales, M.A., Bonilla, F. and Provencio, M. (2009) Extracellular Tumor-Related mRNA in Plasma of Lymphoma Patients and Survival Implications. PLoS ONE, 4, e8173.
https://doi.org/10.1371/journal.pone.0008173
|
[44]
|
Roscheweski, M., Dunleavy, K., Pittaluga, S., Moorhead, M., Pepin, F., Kong, K., Shovlin, M., Jaffe, E.S., Staudt, L.M., Lai, C., Steinberg, S.M., Chen, C.C., Zheng, J., Willis, T.D., Faham, M. and Wilson, W.H. (2013) Circulating Tumour DNA and CT Monitoring in Patients with Untreated Diffuse Large B-Cell Lymphoma: A Correlative Biomarker Study. The Lancet Oncology, 16, 541-549.
https://doi.org/10.1016/S1470-2045(15)70106-3
|
[45]
|
Colocci, N., Glantz, M. and Recht, L. (2004) Prevention and Treatment of Central Nervous System Involvement by Non-Hodgkin’s Lymphoma: A Review of the Literature. Seminars in Neurology, 24, 395-404.
https://doi.org/10.1055/s-2004-861534
|
[46]
|
Chamberlain, M.C. (2005) Neoplastic Meningitis. Journal of Clinical Oncology, 23, 3605-3613. https://doi.org/10.1200/JCO.2005.01.131
|
[47]
|
Sancho, J.M., Morgades, M., Alonso, N., Deben, G., Fernández de Sevilla, A., Vazquez, L., et al., on Behalf of Investigators of QUIT Study (PETHEMA GELTAMO and GOTEL Groups) (2008) Prospective Study on the Practice of Central Nervous System Prophylaxis and Treatment in Non-Hodgkin’s Lymphoma in Spain. Medicina Clínica (Barc), 131, 441-446. https://doi.org/10.1157/13126952
|
[48]
|
Feugier, P., Virion, J.M., Tilly, H., Haioun, C., Marit, G., Macro, M., et al. (2004) Incidence and Risk Factors for Central Nervous System Occurrence in Elderly Patients with Diffuse Large-B-Cell Lymphoma: Influence of Rituximab. Annals of Oncology, 15, 129-133. https://doi.org/10.1093/annonc/mdh013
|
[49]
|
Boehme, V., Schmitz, N., Zeynalova, S., Loeffler, M. and Pfreundschuh, M. (2009) CNS Events in Elderly Patients with Aggressive Lymphoma Treated with Modern Chemotherapy (CHOP-14) with or without Rituximab: An Analysis of Patients Treated in the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood, 113, 3896-3902.
https://doi.org/10.1182/blood-2008-10-182253
|
[50]
|
Villa, D., Connors, J.M., Shenkier, T.N., Gascoyne, R.D., Sehn, L.H. and Savage, K.J. (2010) Incidence and Risk Factors for Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma: The Impact of the Addition of Rituximab to CHOP Chemotherapy. Annals of Oncology, 21, 1046-1052.
https://doi.org/10.1093/annonc/mdp432
|
[51]
|
Lemma, S.A., Pasanen, A.K., Haapasaari, K.M., Sippola, A., Sormunen, R., Soini, Y., Jantunen, E., Koivunen, P., Salokorpi, N., Bloiqu, R., Turpeenniemi-Hujanen, T. and Kuittinen, O. (2016) Similar Chemokine Receptor Profiles in Lymphomas with Central Nervous System Involvement—Possible Biomarkers for Patient Selection for Central Nervous System Prophylaxis, a Retrospective Study. European Journal of Haematology, 96, 492-501. https://doi.org/10.1111/ejh.12626
|
[52]
|
Purhonen, A.K., Juutilainen, A., Vanska, M., Lehtikangas, M., Lakkisto, P., Hamalainen, S., Koivula, I., Jantunen, E. and Pulkki, K. (2015) Human Plasma Cell-Free DNA as a Predictor of Infectious Complications of Neutropenic Fever in Hematological Patients. Infectious Diseases, 47, 255-259.
https://doi.org/10.3109/00365548.2014.985711
|
[53]
|
Machado, A.S., Da Silva, R., Maghalares, M.C., et al. (2010) Ciculating Cell-Free and Epstein-Barr Virus DNA in Paediatric B-Non-Hodgkin Lymphomas. Leukemia & Lymphoma, 51, 1020-1027. https://doi.org/10.3109/10428191003746331
|
[54]
|
Mussolin, L., Pillon, M., d’Amore, E.S., et al. (2011) Minimal Disseminated Disease in High-Risk Burkitt’s Lymphoma Identifies Patients with Different Prognosis. Journal of Clinical Oncology, 29, 1779-1784.
https://doi.org/10.1200/JCO.2010.32.8161
|
[55]
|
Mussolin, L., Bonvini, P., ALi-Tahar, K., et al. (2009) Kinetics of Humoral Response to ALK and Its Relationship with Minimal Residual Disease in Paediatric ALCL. Leukemia, 23, 400-402. https://doi.org/10.1038/leu.2008.184
|
[56]
|
Ali-Tahar, K., Damm-Welk, C., Burkhardt, B., et al. (2010) Correlation of the Autoantibody Response to the ALK Oncoantigen in Peditaric Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma with Tumor Dissemination and Relapse Risk. Blood, 115, 3314-3319. https://doi.org/10.1182/blood-2009-11-251892
|
[57]
|
Mussolin, L., Pillon, M., d’Amore, E.S., et al. (2005) Prevalence and Clinical Implications of Bone Marrow Involvement in Peditaric Anaplastic Large Cell Lymphoma. Leukemia, 19, 1643-1647. https://doi.org/10.1038/sj.leu.2403888
|
[58]
|
Mussolin, L., Burnelli, R., Pillon, M., Carraro, E., Farruggia, P., Todesco, A., Muscarin, M. and Rosolen, A. (2013) Plasma Cell-Free DNA in Paediatric Lymphomas. Journal of Cancer, 4, 323-329. https://doi.org/10.7150/jca.6226
|
[59]
|
Mouliere, F., El Messaoudi, S., Pang, D., Dritschilo, A. and Thierry, A.R. (2014) Multi-Marker Analysis of Circulating Cell-Free DNA toward Personalized Medicine for Colorectal Cancer. Molecular Oncology, 8, 927-941.
https://doi.org/10.1016/j.molonc.2014.02.005
|
[60]
|
Kuppers, R., Klein, U., Hansmann, M.L. and Rajewsky, K. (1999) Cellular Origin of Human B-Cell Lymphomas. The New England Journal of Medicine, 341, 1520-1529. https://doi.org/10.1056/NEJM199911113412007
|
[61]
|
Stevenson, F.K., Sahota, S.S., Ottensmeier, C.H., Zhu, D., Forconi, F. and Hamblin, T.J. (2001) The Occurrence and Significance of V Gene Mutations in B Cell-Derived Human Malignancy. Advances in Cancer Research, 83, 81-116.
|
[62]
|
Kutz, D.M. (2015) Noninvasive Monitoring of DLBCL by Immunoglobulin HighThroughput Sequencing. Blood, 125, 3679-3687.
https://doi.org/10.1182/blood-2015-03-635169
|
[63]
|
Rossi, D., Diop, F., Spaccarotella, E., Monti, S., Zanni, M., Rasi, S., Deambrogi, C., Spina, V., Bruscaggin, A., Favini, Ch., Serra, R., Rampni, A., Baldorini, R., Foa, R. and Gaidano, G. (2017) Diffuse Large B-Cell Lymphoma Genotyping on the Liquid Biopsy. Blood, published online. https://doi.org/10.1182/blood-2016-05-719641
|
[64]
|
Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., Sabet, H., Tran, T., Yu, X., Powell, J.I., Yang, L., Marti, G.E., Moore, T., Hudson Jr., J., Lu, L., Lewis, D.B., Tibshirani, R., Sherlock, G., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.D., Wamke, R., Levy, R., Wilson, W., Grever, M.R., Byrd, J.C., Botstein, D., Brown, P.O. and Staudt, L.M. (2000) Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling. Nature, 403, 503-511. https://doi.org/10.1038/35000501
|
[65]
|
Bohers, E., Vially, P.J., Dubois, S., Bertrand, P., Maingonnat, C., Mareschal, S., Ruminy, P., Picquenot, J.M., Bastard, Ch., Desmots, F., Fest, T., Leroy, K., Tilly, H. and Jardin, F. (2015) Somatic Mutations of Cell-Free Circulating DNA Detected by Next-Generation Sequencing Reflect the Genetic Changes in Both Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphomas at the Time of Diagnosis. Haematologica, 100, e280-e284.
https://doi.org/10.3324/haematol.2015.123612
|
[66]
|
Armand, P., Oki, Y., Neuberg, D.S., et al. (2013) Detection of Circulating Tumour DNA in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma. British Journal of Haematology, 163, 123-126. https://doi.org/10.1111/bjh.12439
|
[67]
|
Faham, M., Zheng, J., Moorhead, M., et al. (2012) Deep-Sequencing Approach for Minimal Residual Disease Detection in Acuate Lymphoblastic Leukemia. Blood, 120, 5173-5180. https://doi.org/10.1182/blood-2012-07-444042
|
[68]
|
Logan, A.C., Zhang, B., Narasimhan, B., et al. (2013) Minimal Residual Disease Quantification Using Consensus Primers and High-Throughput IGH Sequencing Predicts Post-Transplant Relapse in Chronic Lymphocytic Leukemia. Leukemia, 27, 1659-1665. https://doi.org/10.1038/leu.2013.52
|
[69]
|
Martinez-Lopez, J., Narasimhan, B., et al. (2014) Prognostic Value of Deep Sequencing Method for Minimal Residual Disease Detection in Multiple Mieloma. Blood, 123, 3073-3079. https://doi.org/10.1182/blood-2014-01-550020
|
[70]
|
Mancuso, P., Calleri, A., Antoniotti, P., Quarna, J., Prumeri, G. and Bertolini, F. (2010) If It Is in the Marrow, Is It Also in the Blood? An Analysis of 1000 Paired Samples from Patients with B-Cell Non-Hodgkin Lymphoma. BMC Cancer, 10, 644. https://doi.org/10.1186/1471-2407-10-644
|
[71]
|
Kristensen, L.S., Hansen, J.W., Kristensen, S.S., Tholstrup, D., Harslof, L.B., Pedersen, O.B., De Nully Brown, P. and Gronbaek, K. (2016) Aberrant Methylation of Cell-Free Circulating DNA in Plasma Predicts Poor Outcome in Diffuse Large B Cell Lymphoma. Clinical Epigenetics, 8, 95.
https://doi.org/10.1186/s13148-016-0261-y
|
[72]
|
Favier, O., Heutte, N., Stamatoullas-Bastard, A., Carde, P., Van’t Veer, M.B., Aleman, B.M., Noordijk, E.M., Thomas, J., Fermé, C. and Henry-Amar, M. (2009) European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Survival after Hodgkin Lymphoma: Causes of Death and Excess Mortality in Patients Treated in 8 Consecutive Trials. Cancer, 115, 1680-1691.
https://doi.org/10.1002/cncr.24178
|
[73]
|
Younes, A., Bartlett, N.L., Leonard, J.P., Kennedy, D.A., Lynch, C.M., Sivers, E.L. and Forero-Torres, A. (2010) Brentuximab Vedotin (SGN-35) for Relapsed CD30Positive Lymphomas. The New England Journal of Medicine, 363, 1812-1821.
https://doi.org/10.1056/NEJMoa1002965
|
[74]
|
Minich, S.S. (2012) Brentuximab Vedotin: A New Age in the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma. Annals of Pharmacotherapy, 46, 377-383. https://doi.org/10.1345/aph.1Q680
|
[75]
|
Camus, V., Stamatoullas, A., Mareschal, S., Viailly, P.J., Srafan-Vasseur, N., Bohers, E., Dubois, S., Picquenot, J.M., Ruminy, P., Maingonnat, C., Bertrand, P., Comic, M., Tallon-Simon, V., Becker, S., Veresezan, L., Frebour, T., Vera, P., Bastard, P., Tilly, H. and Jardin, F. (2016) Detection and Prognostic Value of Recurrent Exportin 1 Mutations in Tumor and Cell-Free Circulating DNA of Patients with Classical Hodgkin Lymphoma. Haematologica, 101, 1094-1101.
https://doi.org/10.3324/haematol.2016.145102
|
[76]
|
Jones, K., Nourse, J.P., Keane, C., Bhatnagar, A. and Gandhi, M.K. (2013) Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma. Predictive Biomarkers and Personalized Medicine, 20, 253-264.
|
[77]
|
Van Eijndhoven, M.A.J., Zijlstra, J.M., Groenewegen, N.J., Drees, E.E.E., van Niele, S., Rubina Baglio, D., van der Voorn, H., Libregts, S.F.W.M., Wauben, M.H.M., de Menezes, R.X., van Weering, J.R.T., Nieuwland, R., Visser, L., van den Berg, A., de Jong, D. and Michiel Pegtel, D. (2016) Plasma Vesicle miRNAs for Therapy Response Monitoring in Hodgkin Lymphoma Patients. JCI Insight, 1, e89631.
https://doi.org/10.1172/jci.insight.89631
|
[78]
|
Primerano, S., Burnelli, R., Carraro, E., Pillon, M., Elia, C., Farruggia, P., Sala, A., Vinti, L., Buffardi, S., Basso, G., Mascarin, M. and Mussolin, L. (2016) Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma. Journal of Cancer, 7, 364-366. https://doi.org/10.7150/jca.13593
|
[79]
|
Calvano, A., La Rocca, F., Simeon, V., Girasole, M., Dinarelli, S., Laurenzana, I., De Stradis, A., De Luca, L., Trino, S., Traficante, A., D’Arena, G., Mansueto, G., Villani, O., Pietrantuono, G., Laurenti, L., Del Vecchio, L. and Musto, P. (2017) MicroRNA-155 in Serum-Derived Extracellular Vesicles as a Potential Biomarker for Hematological Malignancies—A Short Report. Cellular Oncology, 40, 97-103.
https://doi.org/10.1007/s13402-016-0300-x
|
[80]
|
Vasioukhin, V., Anker, P., Maurice, P., Lyautey, J., Lederrey, C. and Stroun, M. (1994) Point Mutations of the N-Ras Gene in the Blood Plasma of Patients with Myelodisplastic Síndrome Ora Cute Myelogenous Leukaemia. British Journal of Haematology, 86, 774-779. https://doi.org/10.1111/j.1365-2141.1994.tb04828.x
|
[81]
|
Koutova, L., Sterbova, M., Pazourkova, E., Pospisilova, S., Svobodova, I., Horinek, A., Lysak, D. and Korabecna, M. (2015) The Impact of Standard Chemotherapy on miRNA Signature in Plasma in AML Patients. Leukemia Research, 39, 1389-1395.
https://doi.org/10.1016/j.leukres.2015.08.009
|
[82]
|
Mithraprabhu, S., Khong, T., Ramachandran, M., Chow, A., Klarica, D., Mai, L., Walsh, S., Broemeling, D., Marziali, A., Wiggin, A., Hocking, J., Kalff, A., Durie, B. and Spencer, A. (2017) Circulating Tumour DNA Analysis Demonstrates Spatial Mutational Heterogeneity That Coincides with Disease Relapse in Myeloma. Leukemia, Epub ahead of print. https://doi.org/10.1038/leu.2016.366
|
[83]
|
Oberle, A., Brandt, A., Voigtiaender, M., Thiele, B., Radioff, J., Schulenkorf, A., Alawi, M., Marz, M., Ford, C.T., Krohn-Grimberghe, A. and Binder, M. (2017) Monitoring Multiple Myeloma by Next-Generatin Sequencing of V(D)J Rearrangements from Circulating Myeloma Cells and Cell-Free Myeloma DNA. Hematologica, Epub ahead of print. https://doi.org/10.3324/haematol.2016.161414
|
[84]
|
Isin, M., Ozqur, E., Cetin, G., Erten, N., Aktan, M., Gezer, U. and Dalay, N. (2014) Investigation of Circulating lncRNAs in B-Cell Neoplasms. Clinica Chimica Acta, 431, 255-259.
|